KVUE - Kenvue Health Enterprise Value

Kenvue Health - graphic logo of issuer KVUE

Serving as an assessment tool, the Kenvue Inc. (KVUE) price chart, with a market metric of 44823.63, is based on strong positions within pharmacy chains and strict FDA oversight. Stable revenue is ensured by generational continuity in the use of Tylenol and Listerine. Business efficiency is supported by experienced management focused on optimizing internal processes and developing key trademarks.

KVUE (kenvue.com) Total Company Value history from 11/23/2025 to 10/28/2026

Kenvue Inc. (KVUE) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Kenvue Inc|KVUE - Consensus Target
- market capitalization data:
Market Capitalization Kenvue|KVUE - Enterprise Value
- book capitalization data:
Net Asset Value per Share Kenvue|KVUE - Company Book Value|Market Capitalization to Net Assets kenvue.com|KVUE - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Kenvue Inc.|KVUE - Long-Term Debt to Capital|Short-Term Debt to Capital kenvue.com|KVUE - Company Debts|Debt to Net Assets Ratio Kenvue|KVUE - Company Long-Term Debt|Company Current Liabilities Kenvue
Comprehensive company analysis:Kenvue Inc (KVUE)
Original product of Kenvue Inc.

Enterprise value combines market capitalization and net debt, determining the actual cost of a full business buyout while excluding operational noise. By analyzing the total enterprise value at the 44823.63 level, an investor assesses the organic growth efficiency of Kenvue Inc. and the optimization of logistics following its spin-off from the parent corporation in the absence of merger and acquisition deals.

Competitor analysis for Kenvue Inc.

HLN - Total Company Value|Verona Pharma Corp - Real Price to Acquire Entire Company|MENS - Enterprise Value|Enterprise Value LGND|AMRX (amneal.com) - Total Enterprise Value|Total Company Value Perrigo PRGO|Full Business Value Alvotech S.A.|Liquidia Technologies (LQDA) - Enterprise Value|Value Adjusted for Debt and Cash Galapagos Corp (GLPG)|Enterprise Value ANIP (ANI Pharmaceuticals)|mannkindcorp.com - Enterprise Value|Total Company Value Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX: Value Adjusted for Debt and Cash|SPRY (ARS Pharma) - Total Company Value|Theravance Corp (TBPH) - Real Price to Acquire Entire Company|AQST (Aquestive Therapeutics) - Enterprise Value|Enterprise Value scPharma (SCPH)|Tectonic Therapeutic, Inc. (TECX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TNXP (Tonix Pharma)|SXTC: Total Company Value|EPRX - Total Enterprise Value|Real Price to Acquire Entire Company BioHarvest Sciences BHST|EXOZ - Aggregate Business Value|Enterprise Value oramed.com ORMP|Entera Bio (ENTX) - Value Adjusted for Debt and Cash|Enterprise Value HYFT (MindWalk)|Total Enterprise Value ABVC|Cumberland Pharmaceuticals (CPIX) - Total Company Value|Value Adjusted for Debt and Cash QNTM (quantumbiopharma.com)|Total Company Value FGEN (FibroGen)|Enterprise Value Telomir Pharmaceuticals Inc TELO|RANI (Rani Therapeutics Inc) - Enterprise Value|SNYR: Total Enterprise Value|Total Company Value rallybio.com|Business Value Lexaria Bioscience Corp.|Real Price to Acquire Entire Company Pulmatrix|Total Company Value Pheton (PTHL)|Real Price to Acquire Entire Company APM|Enterprise Value Lyra Therapeutics Inc (LYRA)|IBO: Enterprise Value|TNFA - Total Enterprise Value|Real Price to Acquire Entire Company cbdMD Corp (YCBD)|PRFX - Value Adjusted for Debt and Cash|altamiratherapeutics.com - Enterprise Value|LIPO (Lipella Pharma) - Company Buyout Price|Total Company Value OptiNose, Inc. (OPTN)|Business Value pieris.com|Enterprise Value PROC (Procaps)|Real Price to Acquire Entire Company Petros Pharmaceuticals Inc PTPI|Real Price to Acquire Entire Company QLI|ACELYRIN Inc. - Company Buyout Price|TFF Pharmaceuticals - Total Company Value